Answers are grounded in this paper and cite their sources.
= .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).
No takes yet. Share an insight, caveat, or question.
Jabbour et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: